The Return Of Martin Shkreli
This article was originally published in Start Up
Executive Summary
Biotech entrepreneur Martin Shkreli hopes to recreate his Retrophin success with his new venture, Turing Pharmaceuticals, but can he dodge past potholes as he seeks to raise venture capital?